MET and lung carcinoma: Numerous rare fusions involving receptor tyrosine kinase (RTK) have been detected in lung cancer, including fibroblast growth factor receptor (FGFR), neuregulin 1 (NRG1), and MET Proto-Oncogene, Receptor Tyrosine Kinase (MET).